Refine
Has Fulltext
- yes (43)
Is part of the Bibliography
- yes (43)
Year of publication
Document Type
- Journal article (43)
Language
- English (43)
Keywords
- psoriasis (4)
- Merkel cell carcinoma (3)
- immunohistochemistry (3)
- therapy (3)
- COVID-19 (2)
- Germany (2)
- PD-L1 (2)
- T cells (2)
- bullous pemphigoid (2)
- dermatology (2)
- inflammation (2)
- melanoma (2)
- B cells (1)
- B-cell lymphoma (1)
- B-cells (1)
- B7-H1 Antigen (1)
- CD10 (1)
- CD274 (1)
- CD30 (1)
- CD8(+) (1)
- CTLA-4 Antigen (1)
- Clinical trials (1)
- Crohn disease (1)
- Cutaneous lymphoma (1)
- Cutaneous metastatic Crohn’s disease (1)
- Cx43 (1)
- Drug Therapy, Combination (1)
- EBER in situ hybridization (1)
- ERBB receptors (1)
- EVER1 (1)
- EVER2 (1)
- Epigenetic regulation (1)
- FoxO3 (1)
- HDAC (1)
- Histone deacetylase (1)
- Human papillomavirus (1)
- IFN (1)
- Immune-related adverse event (1)
- Ipilimumab (1)
- JAK2 (1)
- Kaposi sarcoma (1)
- Kerinokeratosis papulosa (1)
- LRIG1 (1)
- LSD1 (1)
- Lysine-specific methylase (1)
- Melanoma (1)
- Minimal change disease (1)
- Molecular imaging (1)
- Mycobacterium marinum (1)
- Nfatc1 (1)
- Nivolumab (1)
- PD-1 (1)
- PEComa (1)
- PRAME (1)
- Positron emission tomography (1)
- Programmed Cell Death 1 Receptor (1)
- RNA probe (1)
- S2k guidelines (1)
- SARS-CoV-2 (1)
- Skin (1)
- Skin Neoplasms (1)
- Somatostatin receptor expression (1)
- T-antigens (1)
- TP53 (1)
- TRRAP (1)
- Th17 (1)
- Tregs (1)
- Tubulin (1)
- United States (1)
- Waxy papulosis of childhood (1)
- acitretin (1)
- adverse event (1)
- allergies (1)
- allergy (1)
- aluminum granuloma (1)
- antitumor immunity (1)
- autoimmune disease (1)
- autoimmune diseases (1)
- autoimmune skin blistering disease (1)
- avelumab (1)
- biologics (1)
- biomarker (1)
- breast cancer (1)
- cancer microenvironment (1)
- cell membranes (1)
- cell rich blue nevus (1)
- cell staining (1)
- chemokine (1)
- cicatricial pemphigoid (1)
- classification (1)
- common blue nevus (1)
- comorbid diseases (1)
- comorbidity (1)
- cutaneous PEComa (1)
- cutaneous T-cell-lymphoma (1)
- cutaneous adverse events (1)
- cutaneous angiosarcoma (1)
- cutaneous lupus erythematosus (1)
- cutaneous lymphomas (1)
- diagnosis (1)
- differential gene expression (1)
- disease severity (1)
- drug therapy (1)
- drug-induced liver injury (DILI) (1)
- endemic pemphigus foliaceus (1)
- environmental factors (1)
- eosinophils (1)
- experience (1)
- fatty liver disease (1)
- genetic association (1)
- health economics (1)
- health insurance (1)
- health-care costs (1)
- hemangioma (1)
- histologic findings (1)
- immune cell infiltration (1)
- immunology (1)
- immunotherapy (1)
- improvement (1)
- indirect costs (1)
- inflammatory disease (1)
- inpatients (1)
- interferon-\(\beta\) (1)
- interleukins (1)
- ipilimumab (1)
- keratinocytes (1)
- laminin 332 (1)
- large cell transformation (1)
- leg cramps (1)
- lesions (1)
- lichen planus (1)
- life (1)
- long-term outcome (1)
- lung cancer (1)
- lymphocytes (1)
- lymphoid hyperplasia (1)
- malignancy (1)
- melanin (1)
- melanocytes (1)
- melanocytic markers (1)
- melanoma cells (1)
- melanomas (1)
- membrane proteins (1)
- mepacrine (1)
- metabolic disease (1)
- metastatic (1)
- methylation (1)
- moderate (1)
- mouse model (1)
- mucous membrane pemphigoid (1)
- multicenter (1)
- multiple sclerosis (1)
- mycosis fungoides (1)
- neurologic disease (1)
- nivolumab (1)
- oesophagogastroduodenoscopy (1)
- orofacial granulomatosis (1)
- outpatients (1)
- over-the-counter drugs (1)
- p53 (1)
- panel sequencing (1)
- patient preferences (1)
- pemphigus foliaceus (1)
- pemphigus vulgaris (1)
- perivascular epitheloid cell tumour (1)
- pityriasis rubra pilaris (1)
- plaque-type psoriasis (1)
- polymavirus (1)
- primary cutaneous follicular B-cell lymphoma (1)
- pseudolymphoma (1)
- pustular exanthema (1)
- quinacrine (1)
- quinine (1)
- resistance (1)
- responses (1)
- review (1)
- rhabdoid differentiation (1)
- rhabdoid melanoma (1)
- satellitosis (1)
- skin (1)
- skin carcinogenesis (1)
- skin reactions (1)
- smoking (1)
- suppression (1)
- surgical and invasive medical procedures (1)
- survival (1)
- systemic sclerosis (1)
- targeted sequencing (1)
- tertiary lymphoid structures (1)
- transcription factors (1)
- treatment options (1)
- tumour immunology (1)
- utaneous adverse events (1)
- uveal melanoma (1)
- vesicles (1)
- virus (1)
Institute
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (43)
- Medizinische Klinik und Poliklinik II (6)
- Pathologisches Institut (6)
- Comprehensive Cancer Center Mainfranken (2)
- Institut für Klinische Epidemiologie und Biometrie (2)
- Institut für Virologie und Immunbiologie (2)
- Kinderklinik und Poliklinik (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Frauenklinik und Poliklinik (1)
- Institut für Humangenetik (1)
Sonstige beteiligte Institutionen
Background: Primary cutaneous follicular B-cell lymphoma (PCFBCL) represents an indolent subtype of Non-Hodgkin’s lymphomas, being clinically characterized by slowly growing tumors of the skin and common cutaneous relapses, while only exhibiting a low propensity for systemic dissemination or fatal outcome. Up to now, only few studies have investigated underlying molecular alterations of PCFBCL with respect to somatic mutations. Objectives: Our aim was to gain deeper insight into the pathogenesis of PCFBCL and to delineate discriminatory molecular features of this lymphoma subtype. Methods: We performed hybridization-based panel sequencing of 40 lymphoma-associated genes of 10 cases of well-characterized PCFBCL. In addition, we included two further ambiguous cases of atypical B-cell-rich lymphoid infiltrate/B-cell lymphoma of the skin for which definite subtype attribution had not been possible by routine investigations. Results: In 10 out of 12 analyzed cases, we identified genetic alterations within 15 of the selected 40 target genes. The most frequently detected alterations in PCFBCL affected the TNFRSF14, CREBBP, STAT6 and TP53 genes. Our analysis unrevealed novel mutations of the BCL2 gene in PCFBCL. All patients exhibited an indolent clinical course. Both the included arbitrary cases of atypical B-cell-rich cutaneous infiltrates showed somatic mutations within the FAS gene. As these mutations have previously been designated as subtype-specific recurrent alterations in primary cutaneous marginal zone lymphoma (PCMZL), we finally favored the diagnosis of PCMZL in these two cases based on these molecular findings. Conclusions: To conclude, our molecular data support that PCFBCL shows distinct somatic mutations which may aid to differentiate PCFBCL from pseudo-lymphoma as well as from other indolent and aggressive cutaneous B-cell lymphomas. While the detected genetic alterations of PCFBCL did not turn out to harbor any prognostic value in our cohort, our molecular data may add adjunctive discriminatory features for diagnostic purposes on a molecular level.
Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.
Bullous pemphigoid is the most common autoimmune blistering disease in industrialized countries and particularly affects the elderly. In this patient population, comorbid diseases are frequent and may complicate management and treatment of bullous pemphigoid. A better understanding why distinct diseases are more frequent in bullous pemphigoid patients may lead to new pathophysiological insights and - as a consequence - result in better patient care. The association of bullous pemphigoid with neurological and psychiatric diseases is well known and confirmed by several case-control studies. Association with further diseases such as malignancy and metabolic diseases are still discussed controversially. In recent years new relationships between bullous pemphigoid and autoimmune as well as inflammatory skin diseases have been reported. This review provides a systematic overview on studies addressing comorbidity in bullous pemphigoid patients. Increasing the awareness of both, common and rare comorbid diseases, may enable clinicians to optimize patient support and individualized treatment of bullous pemphigoid.